CITY-RBP4 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,695 results for “CITY-RBP4”

Trials

View all 682 →

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

48 participants · First posted Sep 23, 2026

Related Mechanisms of RBP4 in Glycolipid Metabolism

200 participants · First posted Oct 12, 2022

Serum CTRP3 and RBP4 Levels in Obesity and Hypertension

2,000 participants · First posted Aug 27, 2014

Drugs

View all 72 →

RBP4 inhibitors(Takeda Pharmaceutical)

BAFF-R targeted monoclonal antibody (City of Hope)

CAR-NK cell therapy (City of Hope)

Organizations

View all 150 →

RBP4 PTY LTD

Australia

MATSUMOTO CITY

Japan

YOKOHAMA CITY

Japan

News

View all 791 →

Clinical-Stage RNAi Developer City Therapeutics Files for Nasdaq IPO

Kansas City Partners Launch Integrated Theranostics Platform for Adult and Pediatric Patients

Sublingual Immunotherapy Faces Hurdles in Gaining Full FDA Approval

Page 1 of 170